Innovent Biologics, Inc. (HKEX: 01801), a globally recognized biopharmaceutical company, and IASO Biotechnology, a leader in innovative cell therapies and antibody products, have announced a significant enhancement in their partnership. This collaboration includes IASO Bio’s acquisition of certain rights to FUCASO (Equecabtagene Autoleucel) from Innovent, along with a license for the associated intellectual property, coupled […]
Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical Products Administration (NMPA) approving a new indication for XPOVIO (selinexor). This approval allows the use of XPOVIO as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), one of the most […]
Innovent Biologics, Inc. (HKEX: 01801) has announced remarkable results from the CLEAR-1 Phase 3 registrational study of its novel drug, picankibart (R & D code: IBI112), signaling a major breakthrough in psoriasis treatment. The study demonstrated that picankibart, a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, met all primary and key secondary endpoints, showcasing its […]
Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company, announced that its New Drug Application (NDA) for IBI311, a pioneering treatment for Thyroid Eye Disease (TED), has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Drug Administration (NMPA). This marks a significant milestone as IBI311 is the first […]
In a strategic move to enhance its presence in the biopharmaceutical sector, Novo Holdings A/S has secured a majority stake of approximately 60% in Single Use Support, a pioneering Austrian company specializing in bioprocessing solutions. The acquisition underscores Novo Holdings’ commitment to advancing healthcare technologies and marks its first control investment in the DACH region, […]
In an important development for the treatment of neovascular age-related macular degeneration (nAMD), Innovent Biologics, Inc., a leading biopharmaceutical company, has announced successful results from the second Phase 2 clinical study of Efdamrofusp Alfa, a high-dose recombinant human VEGFR-Fc-Human CR1 fusion protein injection (R&D code: IBI302). This study, involving more than 360 Chinese subjects with […]
Urovant Sciences has secured global licensing rights from Ion Channel Innovations for the development and commercialization of a promising gene therapy, hMaxi-K. This therapy is currently under development as a potential treatment for patients with overactive bladder (OAB) who have not found relief through traditional oral pharmacologic therapies. This comes at a time when there […]
